HBM Holdings Limited provided consolidated earnings guidance for the year ended December 31, 2025. Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between USD 88 million (equivalent to approximately HKD 685 million) and USD 95 million (equivalent to approximately HKD 739 million), as compared to a profit of approximately USD 2.7 million for the year ended December 31, 2024. Total adjusted profit is expected to range between USD 91 million (equivalent to approximately HKD 708 million) and USD 98 million (equivalent to approximately HKD 763 million).
The anticipated increase in profit is primarily attributable to: Continued growth of recurring revenue stream of the Company, such as the platform-based research collaboration with AstraZeneca and Bristol Myers Squibb. Accelerated expansion of global partner network, as the revenue generated from out-licensing and collaboration of innovative products has transformed into recurring revenue stream of the Company, such as the licensing collaboration with Otsuka, the licensing collaboration with Windward Bio. Rapid business growth of Nona Biosciences, such as the revenue generated from both technology license and platform-based service, as well as the milestone inflow from existing collaborations, such as the research and technology license collaboration with Pfizer.
